Tamiflu Adverse Event One Year Update Requested By Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Pediatric Advisory Committee agrees with FDA that neuropsychiatric events and deaths seen in pediatric patients receiving the antiviral do not represent risk signals.
You may also be interested in...
FDA Recommends Precautionary Language On Neuropsychiatric Events For Tamiflu
Agency’s Pediatric Advisory Committee will also evaluate updated adverse event data from the 2006-2007 flu season for GSK’s Relenza.
FDA Recommends Precautionary Language On Neuropsychiatric Events For Tamiflu
Agency’s Pediatric Advisory Committee will also evaluate updated adverse event data from the 2006-2007 flu season for GSK’s Relenza.
Tamiflu Safety Will Get FDA Committee Review Nov. 27
The Pediatric Advisory Committee will evaluate reported neuropsychiatric and behavioral events from patients taking Roche’s influenza product.